Askel Healthcare Ltd granted Breakthrough Device Designation by the FDA
We are very pleased to learn that our Finnish start-up client Askel Healthcare Ltd was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for their COPLA® cartilage repair device.
This site is owned by aera a/s, and is for commercial and informational purposes only. The content is not intended as legal advice, and it should not be used as such.
aera a/s will at all times do its utmost to keep this site fully updated. However, aera a/s disclaims any direct or indirect damage resulting from entering this site, or using the information contained in the site.
Material from this site can only be reproduced, distributed, or otherwise made public with prior permission from aera a/s.